ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors’ Angiogenic Potential and Homing Ability
Guillaume Hache(Inserm), Benjamin Guillet(Inserm), Jimmy Stalin(Araim Pharmaceuticals (United States)), Françoise Dignat‐George(Inserm), Anthony Cerami(Araim Pharmaceuticals (United States)), Michael Brines(Northwell Health), Philippe Garrigue(Aix-Marseille Université), Youssef Bennis(Centre Hospitalier Universitaire Amiens-Picardie), Anaïs Moyon(Aix-Marseille Université), Florence Sabatier(Aix-Marseille Université), Marcel Blot‐Chabaud(Inserm)
Cited by 26
Related Papers
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
|Proceedings of the National Academy of Sciences|2000|1.4k
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
|Molecular Medicine|2002|1k
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
|Proceedings of the National Academy of Sciences|2001|1k
Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor
|Proceedings of the National Academy of Sciences|2004|654